Table 2.
IC50s and CC25s of FQs against WT and mutant DNA gyrasesa
| Drug | IC50 |
CC25 |
||||||
|---|---|---|---|---|---|---|---|---|
| WT | Ala91Val | Asp95Gly | Asp95Asn | WT | Ala91Val | Asp95Gly | Asp95Asn | |
| OFX | 6.8 ± 0.8 | 39.4 ± 15.5 (5.8) | 161.2 ± 44.2 (23.7) | 262.3 ± 105.8 (38.6) | 7.3 ± 0.5 | 75.5 ± 16.8 (10.1) | 240.5 ± 30.7 (32.1) | 269.5 ± 76.5 (35.9) |
| GAT | 1.0 ± 0.1 | 3.1 ± 0.7 (3.1) | 7.5 ± 1.6 (7.5) | 13.8 ± 1.6 (13.8) | 1.1 ± 0.2 | 4.3 ± 0.2 (3.9) | 15.6 ± 3.6 (14.2) | 13.5 ± 3.1 (12.3) |
| MXF | 1.5 ± 0.3 | 5.2 ± 1.0 (3.5) | 21.5 ± 4.7 (14.3) | 34.7 ± 3.1 (23.1) | 1.0 ± 0.1 | 4.5 ± 1.0 (4.5) | 25.5 ± 3.7 (25.5) | 20.8 ± 5.0 (20.8) |
| SIT | 0.4 ± 0.0 | 1.0 ± 0.2 (2.5) | 2.2 ± 0.5 (5.5) | 3.9 ± 0.6 (9.8) | 0.3 ± 0.0 | 0.9 ± 0.0 (3.0) | 2.2 ± 0.6 (7.3) | 2.3 ± 0.4 (7.7) |
a
IC50s and CC25s are in μg/ml, and data in parentheses represent the fold increase compared to WT.